Biotech | May 27, 2022
Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
While Pregabalin will be manufactured at the Aurangabad facility, Iloperidone will be manufactured at the Goa facility
Docosanol Cream, 10% (OTC) has an estimated market size of US$60 million for twelve months ending December 2021 according to IQVIA
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
Subscribe To Our Newsletter & Stay Updated
